RecruitingNCT05816850
Multilayer Biological Characterization of Advanced Follicular Lymphoma: a Translational Study From FIL_FOLL12 Trial
Sponsor
Fondazione Italiana Linfomi - ETS
Enrollment
654 participants
Start Date
Sep 19, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
This is a Multicenter, Retrospective, Biological study ancillary to FOLL12 trial to evaluate the role of EZH2 aberrations in patient with FL treated with immunochemotherapy. Moreover, several novel biomarkers of FL will be investigated.
Eligibility
Min Age: 18 Years
Inclusion Criteria2
- Patient enrolled in the FIL\_FOLL12 trial (documented by the signature of the study informed consent);
- Availability of biological samples: bone marrow aspirate, peripheral blood and/or FFPE diagnostic sample (nodal or extranodal);
Exclusion Criteria1
- None
Interventions
DIAGNOSTIC_TESTEZH2 mutations/CNAs by droplet digital PCR (ddPCR)
Test of EZH2 mutations/CNAs by droplet digital PCR (ddPCR) in peripheral blood and in unsorted bone marrow aspirate samples at enrolment
DIAGNOSTIC_TESTEZH2-derived gene expression signature by RNA-Seq
Test of EZH2-derived gene expression signature by RNA-Seq in a subset of diagnostic FFPE samples
Locations(26)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05816850
Related Trials
A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma
NCT0459464227 locations
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
NCT05006716120 locations
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
NCT060263191 location
Odronextamab in Low Tumor Volume Advanced FL
NCT071286411 location
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
NCT065103613 locations